Compare Recursion Pharmaceuticals Inc (RXRX) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Block Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Block Inc trades at $79.77 (market cap $47.70B). The key difference: Block Inc is far larger — about 27.4× Recursion Pharmaceuticals Inc's market cap, and Block Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XYZ | |
|---|---|---|
Market Cap | $1.74B | $47.70B |
Sector | Health | Technology |
52-Week High | $6.79 | $84.85 |
52-Week Low | $2.84 | $49.04 |
Enterprise Value | $1.26B | $42.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
XYZ stock trades at $80.10, down 3.21% with a bearish technical signal. The company shows mixed fundamentals with strong revenue growth to $24.19B in 2025 but declining net income margins to 1.43%. Recent developments include expanding Cash App credit score access and applying for a national trust bank charter. Analyst consensus remains strongly bullish with 76% buy ratings and a $100.20 price target.
XYZ faces execution risks amid high P/E valuation of 143, though strategic initiatives in financial services provide growth catalysts. The stock offers 25% upside to consensus target but requires monitoring of profitability trends and regulatory approval for banking expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
